Transfusion-related immunomodulation and cancer

Area of Science:

• Immunology
• Transfusion Medicine
• Oncology

Background:

• Blood transfusions can elicit complex immunological responses.
• Transfusion-related immunomodulation (TRIM) is a key immune reaction resulting in immunosuppression.
• TRIM may contribute to adverse clinical outcomes in cancer patients undergoing surgery.

Purpose of the Study:

• To explore the mechanisms of transfusion-related immunomodulation (TRIM).
• To investigate the role of TRIM in cancer patient outcomes.
• To highlight the potential of novel technologies in understanding TRIM.

Main Methods:

• Review of existing literature on TRIM mechanisms.
• Analysis of factors influencing TRIM, including donor and processing variables.
• Consideration of emerging technologies like metabolomics and proteomics.

Main Results:

• TRIM mechanisms involve residual leukocytes, apoptotic cells, immunosuppressive cytokines, microparticles, extracellular vesicles, and hemoglobin.
• TRIM may partially explain negative outcomes in cancer patients receiving transfusions.
• Donor-specific and processing variables influence TRIM.

Conclusions:

• TRIM is a significant biological response to blood transfusion with immunosuppressive effects.
• Further research into TRIM, utilizing advanced techniques, is crucial for understanding its impact on cancer progression.
• Understanding TRIM could lead to improved transfusion strategies and patient care, particularly in oncology.